cranium85
Banned
- Joined
- May 8, 2012
- Messages
- 2
- Reaction score
- 2
- Points
- 0
PEG-MGF – Mechano Growth Factor
Other Names: IGF-1ec
Description: PEG-MGF (Pegylated Mechano Growth Factor) is a variant of IGF-1 (Insulin-like Growth Factor) which leads to an increase in the muscle cells necessary for adult muscles to continue growth beyond their genetic limit. Like other forms of IGF-1, PEG-MGF (also known as IGF-1ec) creates new muscle cells and stimulates muscle growth by promoting nitrogen retention and increasing protein synthesis.
PEG-MGF differs from regular MGF as it has undergone a process of “Pegylation” which extends its half-life from less than 30 minutes to several days.
Useful For: Persons looking to stimulate growth in certain (usually lagging) muscles.
Storage: Vials are freeze-dried and therefore will remain stable at room temperature for 1-2 months. However, for long term storage they should be kept a 2-8 degrees Celsius (refrigerator temperature), where they will remain stable for up to 18 months in powder form. Once mixed with mixing solution, vials should be stored in the refrigerator and not left at room temperature. NOTE: Do not mix up all your vials at once. You should only mix up 1 (one) vial at a time and leave the rest in powder form until you are ready to use the next vial.
Amount of Water to Mix: You can mix 1ml (1cc or 100 units), 2ml (2cc or 200 units), or 3ml (3cc or 300 units) of sterile water, sterile saline (0.09nacl) or bacteriostatic water. The amount of water you mix makes no difference to the products effectiveness. The only thing that will change with the differing amounts of water is the amount you have to inject to get a certain dosage. For ease of dosing, we recommend mixing 1ml of water per vial (unless you have difficulty dissolving the peptide). Note: If the product does not dissolve into 1ml of water within a few minutes, do not shake the vial, but instead try adding another 1ml or 2ml of water and leaving the vial to settle for 24 hours in the refrigerator.
Dosage: Males & Females = 200mcg (0.10ml or “10” units on the Insulin Syringe if you have used 1ml for mixing, 0.20ml or “20” units if you have used 2ml of water for mixing and 0.3ml or “30” units if you have used 3ml of water for mixing).
Number of Dosages per vial: 10 x 200mcg (0.2mg) dosages.
When to Take: After weight training. As a single injection into one muscle group, or split up to inject half of the dose each into the left and right side muscles.
How to Take: Preferably injected intramuscularly. But due to the extended half-life it can be injected subcutaneously into fat (stomach, thigh or buttock) and still make its way to the muscle cell receptors and be effective. Other peptides can be mixed in the same syringe and injected at the same time.
Possible Benefits: Increased muscle mass in lagging muscle groups, injury repair.
Possible Side Effects: None have been noted from the product itself, however temporary irritation (redness, itching or small lumps) at the injection site is always a possibility, especially if injected into fat (sub-q).
Best Combined With: CJC-1295 DAC.
MORE INFROMATION:
Quick summary: MGF is a splice variant of the IGF produced by a frame shift if the IGF gene. MGF increase the muscle stem cell count, so that more may fuse and become part of adult muscle cells. This is a process required for adult muscle cells to continue growing.
Why PEGylate MGF?
MGF exhibits local effects in skeletal muscle and without modification is not systemic (can’t travel through the body). The problem with synthetic MGF is that it is introduced IM and is water based so it goes into the blood stream. MGF is not stable in the blood stream for more than a matter of minutes. Biologically produced MGF is made locally and does not enter the bloodstream and is short acting so stability is not an issue. By PEGylating the MGF we can make synthetic MGF injected IM almost as efficient as local produced MGF. Clinically proven Advanced Pegylation, the technology of polyethylene glycol (PEG) conjugation, holds significant promise in maintaining effective plasma concentrations of systemically administered drugs. It does this by surrounding part of the peptide with a unique structure made of polyethylene glycol, which can be attached to a protein molecule. The result of a correct PEGylation is simlar to the protective mechanism of a turtle shell. The polyethylene glycol groups protect the peptide but don’t surround it completely. The active sites of the peptide are still free to do their biological function. In this case the shell is a negative charged shield against positively charged compounds that would affect the protein. This also provides a nice steric chamber for the peptide to reside in. So it’s a happy turtle
Neurological research has shown that utilizing PEGylated MGF resulted in a longer more stable acting version of the MGF peptide in serum/blood.
Bottom line
PEGylation can improve performance and dosing convenience of peptides, proteins, antibodies, oligonucleotides and many small molecules by optimizing pharmacokinetics, increasing bioavailability, and decreasing immunogenicity and dosing frequency. PEGylation also can increase therapeutic efficacy by enabling increased drug concentration, improved biodistribution, and longer dwell time at the site of action. As a result, therapeutic drug concentrations can be achieved with less frequent dosing—a significant benefit to patients who are taking injected drugs.
The PEG itself does not react in the body and is very safe. PEG has been approved by the US Food and Drug Administration (FDA) as a base or vehicle for use in foods and cosmetics and in injectable, topical, rectal and nasal pharmaceutical formulations. PEG has demonstrated little toxicity, is eliminated intact by the kidneys or in the feces and lacks immunogenicity. The risk associated with current PEGylated drugs are due to the way the drug itself acts not the PEG. MGF, as it is being currently sold, is getting a bad rep from people due to the fact they feel that they are not seeing gains from it. Many people believe that the use of MGF in their cycles or protocols just flat out won't work, however, this is far from the truth.
More MGF information
Complete Overview of MGF or IGF-IEc
From its sequence, MGF is derived from the IGF-I gene by alternative splicing and has different 3' exons to the liver or systemic type (IGF-IEa). It has a 49 base pair insert in the human, and a 52 base pair insert in rodents, within the E domain of exon 5. This insert results in a reading frame shift, with a different carboxy (C) terminal sequence to that of systemic IGF-IEa. MGF and the other IGF isoforms have the same 5' exons that encode the IGF-I ligand-binding domain. Processing of pro-peptide yields a mature peptide that is involved in upregulating protein synthesis. However, there is evidence that the carboxy-terminal of the MGF peptide also acts as a separate growth factor. This stimulates division of mononucleated myoblasts or satellite (stem) cells, thereby increasing the number available for local repair
During the early stage of skeletal muscle development, myoblasts (muscle stem cells) fuse to form syncytial myotubes, which become innervated and develop into muscle fibres. Thereafter, mitotic proliferation of nuclei within the muscle fibres ceases. However, during postnatal (after development) growth, additional nuclei are provided by satellite cells (myoblast) fusing with myotubules. Muscle damage-recovery seems to have a similar cellular mechanism, in that satellite cells become activated and fuse with the damaged muscle fibres (reviewed by Goldring et al. 2002). This is also pertinent to certain diseases such as muscular dystrophy in which muscle tissue is not maintained and which have been associated with a deficiency in active satellite (stem) cells (Megeney et al. 1996; Seale & Rudnicki, 2000) and in myogenic factors (Heslop et al. 2000). Skeletal muscle mass and regenerative capacity have also been shown to decline with age (Sadeh, 1988; Carlson et al. 2001). The reduced capacity to regenerate in older muscle seems to be due to the decreased ability to activate satellite cell proliferation (Chakravarthy et al. 2000). The markedly lower expression of MGF in older rat muscles (Owino et al. 2001) and human muscle (Hameed et al. 2003) in response to mechanical overload has been associated with the failure to activate satellite cells, leading to age-related muscle loss (Owino et al. 2001). Your muscle cels can not grow once they have reached a certain size unless they obtain more nuclei from the myoblast. MGF increases the myblast available to donate their nuclei to the adult muscle cell.
“MGF appears to have a dual action in that, like the other IGF-I isoforms, it upregulates protein synthesis as well as activating satellite cells. However, the latter role of MGF is probably more important as most of the mature IGF-I will be derived from IGF-IEa during the second phase of repair. Nevertheless, it has been shown that MGF is a potent inducer of muscle hypertrophy in experiments in which the cDNA of MGF was inserted into a plasmid vector and introduced by intramuscular injection. This resulted in a 20 % increase in the weight of the injected muscle within 2 weeks, and the analyses showed that this was due to an increase in the size of the muscle fibres (Goldspink, 2001). Similar experiments by other groups have also been carried out using a viral construct containing the liver type of IGF-I, which resulted in a 25 % increase in muscle mass, but this took over 4 months to develop (Musaro et al. 2001). Hence, the dual role MGF plays in inducing satellite cell activation as well as protein synthesis suggests it is much more potent than the liver type or IGF-IEa for inducing rapid hypertrophy.”
These results are based on actual transplantation of the DNA coding for the peptides. This is a permanent effect and much more potent than IM injections of the peptide itself. You will not see a 20% increase in muscle mass through IM injections as claimed above.
PEG-MGF (Mechano Growth Factor)
Dose per injection: 200mcg (0.2mg)
Injections per vial: 10 x 200mcg dosages
Amount to Inject: If you have used 1ml of water for mixing then a 200mcg dosage = 0.10ml (or 10 units on Insulin Syringe). If you have used 2ml of water for mixing then 200mcg = 0.20ml (or 20 units) and if you have used 3ml of water for mixing then 200mcg = 0.30ml (or 30 units).
Injection Frequency
PEG-MGF
200mcg injected post workout.
Other Names: IGF-1ec
Description: PEG-MGF (Pegylated Mechano Growth Factor) is a variant of IGF-1 (Insulin-like Growth Factor) which leads to an increase in the muscle cells necessary for adult muscles to continue growth beyond their genetic limit. Like other forms of IGF-1, PEG-MGF (also known as IGF-1ec) creates new muscle cells and stimulates muscle growth by promoting nitrogen retention and increasing protein synthesis.
PEG-MGF differs from regular MGF as it has undergone a process of “Pegylation” which extends its half-life from less than 30 minutes to several days.
Useful For: Persons looking to stimulate growth in certain (usually lagging) muscles.
Storage: Vials are freeze-dried and therefore will remain stable at room temperature for 1-2 months. However, for long term storage they should be kept a 2-8 degrees Celsius (refrigerator temperature), where they will remain stable for up to 18 months in powder form. Once mixed with mixing solution, vials should be stored in the refrigerator and not left at room temperature. NOTE: Do not mix up all your vials at once. You should only mix up 1 (one) vial at a time and leave the rest in powder form until you are ready to use the next vial.
Amount of Water to Mix: You can mix 1ml (1cc or 100 units), 2ml (2cc or 200 units), or 3ml (3cc or 300 units) of sterile water, sterile saline (0.09nacl) or bacteriostatic water. The amount of water you mix makes no difference to the products effectiveness. The only thing that will change with the differing amounts of water is the amount you have to inject to get a certain dosage. For ease of dosing, we recommend mixing 1ml of water per vial (unless you have difficulty dissolving the peptide). Note: If the product does not dissolve into 1ml of water within a few minutes, do not shake the vial, but instead try adding another 1ml or 2ml of water and leaving the vial to settle for 24 hours in the refrigerator.
Dosage: Males & Females = 200mcg (0.10ml or “10” units on the Insulin Syringe if you have used 1ml for mixing, 0.20ml or “20” units if you have used 2ml of water for mixing and 0.3ml or “30” units if you have used 3ml of water for mixing).
Number of Dosages per vial: 10 x 200mcg (0.2mg) dosages.
When to Take: After weight training. As a single injection into one muscle group, or split up to inject half of the dose each into the left and right side muscles.
How to Take: Preferably injected intramuscularly. But due to the extended half-life it can be injected subcutaneously into fat (stomach, thigh or buttock) and still make its way to the muscle cell receptors and be effective. Other peptides can be mixed in the same syringe and injected at the same time.
Possible Benefits: Increased muscle mass in lagging muscle groups, injury repair.
Possible Side Effects: None have been noted from the product itself, however temporary irritation (redness, itching or small lumps) at the injection site is always a possibility, especially if injected into fat (sub-q).
Best Combined With: CJC-1295 DAC.
MORE INFROMATION:
Quick summary: MGF is a splice variant of the IGF produced by a frame shift if the IGF gene. MGF increase the muscle stem cell count, so that more may fuse and become part of adult muscle cells. This is a process required for adult muscle cells to continue growing.
Why PEGylate MGF?
MGF exhibits local effects in skeletal muscle and without modification is not systemic (can’t travel through the body). The problem with synthetic MGF is that it is introduced IM and is water based so it goes into the blood stream. MGF is not stable in the blood stream for more than a matter of minutes. Biologically produced MGF is made locally and does not enter the bloodstream and is short acting so stability is not an issue. By PEGylating the MGF we can make synthetic MGF injected IM almost as efficient as local produced MGF. Clinically proven Advanced Pegylation, the technology of polyethylene glycol (PEG) conjugation, holds significant promise in maintaining effective plasma concentrations of systemically administered drugs. It does this by surrounding part of the peptide with a unique structure made of polyethylene glycol, which can be attached to a protein molecule. The result of a correct PEGylation is simlar to the protective mechanism of a turtle shell. The polyethylene glycol groups protect the peptide but don’t surround it completely. The active sites of the peptide are still free to do their biological function. In this case the shell is a negative charged shield against positively charged compounds that would affect the protein. This also provides a nice steric chamber for the peptide to reside in. So it’s a happy turtle
Neurological research has shown that utilizing PEGylated MGF resulted in a longer more stable acting version of the MGF peptide in serum/blood.
Bottom line
PEGylation can improve performance and dosing convenience of peptides, proteins, antibodies, oligonucleotides and many small molecules by optimizing pharmacokinetics, increasing bioavailability, and decreasing immunogenicity and dosing frequency. PEGylation also can increase therapeutic efficacy by enabling increased drug concentration, improved biodistribution, and longer dwell time at the site of action. As a result, therapeutic drug concentrations can be achieved with less frequent dosing—a significant benefit to patients who are taking injected drugs.
The PEG itself does not react in the body and is very safe. PEG has been approved by the US Food and Drug Administration (FDA) as a base or vehicle for use in foods and cosmetics and in injectable, topical, rectal and nasal pharmaceutical formulations. PEG has demonstrated little toxicity, is eliminated intact by the kidneys or in the feces and lacks immunogenicity. The risk associated with current PEGylated drugs are due to the way the drug itself acts not the PEG. MGF, as it is being currently sold, is getting a bad rep from people due to the fact they feel that they are not seeing gains from it. Many people believe that the use of MGF in their cycles or protocols just flat out won't work, however, this is far from the truth.
More MGF information
Complete Overview of MGF or IGF-IEc
From its sequence, MGF is derived from the IGF-I gene by alternative splicing and has different 3' exons to the liver or systemic type (IGF-IEa). It has a 49 base pair insert in the human, and a 52 base pair insert in rodents, within the E domain of exon 5. This insert results in a reading frame shift, with a different carboxy (C) terminal sequence to that of systemic IGF-IEa. MGF and the other IGF isoforms have the same 5' exons that encode the IGF-I ligand-binding domain. Processing of pro-peptide yields a mature peptide that is involved in upregulating protein synthesis. However, there is evidence that the carboxy-terminal of the MGF peptide also acts as a separate growth factor. This stimulates division of mononucleated myoblasts or satellite (stem) cells, thereby increasing the number available for local repair
During the early stage of skeletal muscle development, myoblasts (muscle stem cells) fuse to form syncytial myotubes, which become innervated and develop into muscle fibres. Thereafter, mitotic proliferation of nuclei within the muscle fibres ceases. However, during postnatal (after development) growth, additional nuclei are provided by satellite cells (myoblast) fusing with myotubules. Muscle damage-recovery seems to have a similar cellular mechanism, in that satellite cells become activated and fuse with the damaged muscle fibres (reviewed by Goldring et al. 2002). This is also pertinent to certain diseases such as muscular dystrophy in which muscle tissue is not maintained and which have been associated with a deficiency in active satellite (stem) cells (Megeney et al. 1996; Seale & Rudnicki, 2000) and in myogenic factors (Heslop et al. 2000). Skeletal muscle mass and regenerative capacity have also been shown to decline with age (Sadeh, 1988; Carlson et al. 2001). The reduced capacity to regenerate in older muscle seems to be due to the decreased ability to activate satellite cell proliferation (Chakravarthy et al. 2000). The markedly lower expression of MGF in older rat muscles (Owino et al. 2001) and human muscle (Hameed et al. 2003) in response to mechanical overload has been associated with the failure to activate satellite cells, leading to age-related muscle loss (Owino et al. 2001). Your muscle cels can not grow once they have reached a certain size unless they obtain more nuclei from the myoblast. MGF increases the myblast available to donate their nuclei to the adult muscle cell.
“MGF appears to have a dual action in that, like the other IGF-I isoforms, it upregulates protein synthesis as well as activating satellite cells. However, the latter role of MGF is probably more important as most of the mature IGF-I will be derived from IGF-IEa during the second phase of repair. Nevertheless, it has been shown that MGF is a potent inducer of muscle hypertrophy in experiments in which the cDNA of MGF was inserted into a plasmid vector and introduced by intramuscular injection. This resulted in a 20 % increase in the weight of the injected muscle within 2 weeks, and the analyses showed that this was due to an increase in the size of the muscle fibres (Goldspink, 2001). Similar experiments by other groups have also been carried out using a viral construct containing the liver type of IGF-I, which resulted in a 25 % increase in muscle mass, but this took over 4 months to develop (Musaro et al. 2001). Hence, the dual role MGF plays in inducing satellite cell activation as well as protein synthesis suggests it is much more potent than the liver type or IGF-IEa for inducing rapid hypertrophy.”
These results are based on actual transplantation of the DNA coding for the peptides. This is a permanent effect and much more potent than IM injections of the peptide itself. You will not see a 20% increase in muscle mass through IM injections as claimed above.
PEG-MGF (Mechano Growth Factor)
Dose per injection: 200mcg (0.2mg)
Injections per vial: 10 x 200mcg dosages
Amount to Inject: If you have used 1ml of water for mixing then a 200mcg dosage = 0.10ml (or 10 units on Insulin Syringe). If you have used 2ml of water for mixing then 200mcg = 0.20ml (or 20 units) and if you have used 3ml of water for mixing then 200mcg = 0.30ml (or 30 units).
Injection Frequency
PEG-MGF
200mcg injected post workout.
